BPC-157 (Body Protection Compound-157)

Overview

BPC-157, or Body Protection Compound-157, is a synthetic 15-amino-acid peptide derived from a larger protective protein naturally present in human gastric juice. Its amino acid sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, with a molecular weight of 1,419.53 Da and a molecular formula of C₆₂H₉₈N₁₆O₂₂. First characterized by researchers at the University of Zagreb in Croatia, BPC-157 has been the subject of extensive preclinical investigation spanning more than three decades, with over 100 published studies examining its effects on tissue repair, gastrointestinal protection, angiogenesis, and inflammatory modulation in animal models.

Unlike many synthetic peptides, BPC-157 is notable for its stability in human gastric juice, remaining intact for more than 24 hours — a property that has led researchers to investigate oral as well as parenteral routes of administration in experimental settings.

Mechanism of Action

The pharmacological activity of BPC-157 appears to involve multiple interconnected signaling pathways, which researchers have described as a “pleiotropic” mechanism:

Angiogenesis and VEGF Signaling

BPC-157 has been observed to promote the expression of vascular endothelial growth factor receptor 2 (VEGFR2) and stimulate angiogenesis in ischemic tissue models. This pro-angiogenic activity is thought to contribute to its observed effects on wound healing and tissue repair.

Nitric Oxide System Modulation

Research published in Scientific Reports demonstrated that BPC-157 can induce nitric oxide generation through activation of the Src-Caveolin-1-eNOS signaling pathway. Specifically, BPC-157 enhances the phosphorylation of Src, Caveolin-1 (Cav-1), and endothelial nitric oxide synthase (eNOS), while reducing the inhibitory binding between Cav-1 and eNOS. This mechanism promotes vascular endothelial cell migration and may underlie the peptide’s vascular protective effects.

Growth Hormone Receptor Expression

A 2018 study published in Life Sciences found that BPC-157 enhances growth hormone receptor expression in tendon fibroblasts, suggesting a potential mechanism by which it may influence musculoskeletal tissue repair.

Anti-inflammatory Activity

Preclinical studies have reported that BPC-157 modulates inflammatory cytokine expression and demonstrates protective effects against NSAID-induced gastrointestinal toxicity, consistent with its characterization as a cytoprotective agent.

Research Evidence

The bulk of published research on BPC-157 comes from the laboratory of Predrag Sikiric and colleagues at the University of Zagreb. Key areas of investigation include:

Research Area	Key Findings	Model
Wound healing	Accelerated healing of skin incisions, burns, and diabetic wounds	Rat models
Gastrointestinal protection	Protection against ethanol, NSAID, and stress-induced gastric lesions	Rat models
Tendon and ligament repair	Enhanced Achilles tendon healing and growth hormone receptor expression	Rat models
Fistula healing	Promoted healing of gastrointestinal fistulas	Rat models
Vascular protection	Counteracted major vessel occlusion disturbances and ischemia-reperfusion injury	Rat models

A 2025 systematic review in Pharmaceuticals identified 544 published articles related to BPC-157, with 180 PubMed-indexed publications in 2025 alone, reflecting substantial and growing research interest.

It is important to note that the majority of this evidence comes from animal models. As of 2026, no large-scale, peer-reviewed, randomized controlled trials in humans have been published, though early-phase clinical trials in ulcerative colitis and multiple sclerosis have been referenced in review literature.

Potential Applications

Based on preclinical research, areas of investigational interest include:

• Musculoskeletal injury recovery — tendon, ligament, and muscle healing
• Gastrointestinal conditions — ulcers, inflammatory bowel disease, fistulas
• Wound healing — surgical wounds, burns, and diabetic ulcers
• Neuroprotection — peripheral nerve regeneration and CNS injury models
• Organ protection — liver, kidney, and cardiac tissue injury models

These remain investigational applications. No regulatory body has approved BPC-157 for therapeutic use in humans.

Safety Considerations

In preclinical studies, BPC-157 has demonstrated a favorable safety profile. Researchers have reported that a lethal dose (LD1) could not be achieved in toxicity studies, and the peptide has been described as showing “no reported toxicity” in early-phase clinical work for ulcerative colitis and multiple sclerosis.

However, several important caveats apply:

• Long-term human safety data are not available from controlled clinical trials
• The pro-angiogenic properties that support tissue healing could theoretically be contraindicated in contexts where angiogenesis is undesirable (e.g., certain cancers)
• Manufacturing quality and purity vary significantly among commercial sources, as BPC-157 is not produced under pharmaceutical-grade regulation for most markets
• Interactions with other medications and peptides have not been systematically studied

Individuals considering BPC-157 should consult qualified healthcare professionals and recognize that the current evidence base, while extensive in animal models, has significant gaps in human clinical data.